Read more
**Association of American Publishers (AAP) PROSE Award Finalist in Clinical Medicine, 2024**
Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacological modulation of aging, including a discussion of the growing number of novel drug classes with promising anti-aging potential. The aging process is the main risk factor for all chronic diseases affecting the elderly. With lifespans extending across the globe, these chronic diseases are placing a larger burden on individuals and health care systems. Therefore, slowing down the aging rate could be more effective in delaying aging-associated chronic disorders than combating them one by one, which is the conventional approach in a current disease-based pharmacological paradigm.
This book contains the work of the world s leading researchers in the field, including sections on the conceptual and methodological background of anti-aging pharmacology, the basic classes of anti-aging drugs, phytochemicals, outcomes of anti-aging developments and future directions. This book will be of interest to a wide audience, ranging from pharmacologists, medicinal chemists and academic researchers in gerontology, biomedical sciences and those in medical practice.
List of contents
SECTION I. Conceptual and Methodological Backgrounds
1. Can Aging be Cured as a Disease?
2. Geroscience Conceipt
3. Mechanistic Pathways of Aging
4. Biomarkers of Aging Rate
5. Artificial Intelligence-Based Approach in Anti-Aging Pharmacology
6. Big Data Approach
7. OMICs Approaches
SECTION II. Basic Classes of Anti-Aging Drugs
8. Antioxidant Paradox
9. Melatonin
10. Calorie Restriction Mimetics
11. Metformin
12. Rapamycin and rapalogs
13. Nonsteroidal Anti-Inflammatory Drugs
14. Statins
15. Senolytics
16. Epigenetic Drugs
17. Sirtuin Activating Compounds
18. Autophagy Inducers
19. Mitophagy Modulators
20. Telomerase Activators
SECTION III. Phytochemicals
21. Resveratrol
22. Curcumin
23. Quercetin
24. Genistein
25. Epigallocatechin Gallate
26. Berberine
27. Nanodelivery of phytobioactive compounds: a promise in anti-aging medicine
SECTION IV. Outcomes and Concluding Thoughts
28. Ethical perspectives on advances in biogerontology
29. Implications for Public Health Policy
30. The Business of Anti-Aging Science
